BA is thus designed to target tumors via colocalized, simultaneous inhibition of two key immunosuppression pathways in the tumor microenvironment: the PD-L1/programmed cell death 1 protein immune checkpoint pathway (targeting PD-L1) and immunosuppressive axis of TGF-β during tumor pathogenesis [2]. This evidence concerns the gene PDCD1 and neoplasm.